Data completeness
2/8 — Basic
MEPROSPAN (meprobamate) by Bausch Health is clinical pharmacology meprobamate is a carbamate derivative which has been shown in animal studies to have effects at multiple sites in the central nervous system including the thalamus and limbic system. Approved for anxiety disorders, for the short-term relief of the symptoms of anxiety, anxiety and 1 more indications.
Drug data last refreshed 2w ago · AI intelligence enriched 2w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
MEPROSPAN is an extended-release oral capsule formulation of meprobamate, a carbamate derivative anxiolytic that acts on multiple CNS sites including the thalamus and limbic system. It is indicated for short-term relief of anxiety symptoms and anxiety disorders. The extended-release formulation allows for less frequent dosing compared to immediate-release alternatives.
Pre-Launch
Pre-launch stage indicates early commercial infrastructure build with opportunities for brand strategy, market access, and launch team roles at Bausch Health.
Mechanism of Action
CLINICAL PHARMACOLOGY Meprobamate is a carbamate derivative which has been shown in animal studies to have effects at multiple sites in the central nervous system including the thalamus and limbic system.
Worked on MEPROSPAN at Bausch Health? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.